MCID: OBS529
MIFTS: 22

Obsolete: Combined Hyperlipidemia

Categories: Rare diseases

Aliases & Classifications for Obsolete: Combined Hyperlipidemia

MalaCards integrated aliases for Obsolete: Combined Hyperlipidemia:

Name: Obsolete: Combined Hyperlipidemia 59
Mixed Hyperlipidemia 59 55
Combined Hyperlipoproteinemia 59
Mixed Hyperlipoproteinemia 59

Classifications:



External Ids:

Orphanet 59 ORPHA79211

Summaries for Obsolete: Combined Hyperlipidemia

MalaCards based summary : Obsolete: Combined Hyperlipidemia, also known as mixed hyperlipidemia, is related to familial combined hyperlipoproteinemia and hyperlipoproteinemia, type v. The drugs Fenofibrate and Calcium have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes.

Related Diseases for Obsolete: Combined Hyperlipidemia

Graphical network of the top 20 diseases related to Obsolete: Combined Hyperlipidemia:



Diseases related to Obsolete: Combined Hyperlipidemia

Symptoms & Phenotypes for Obsolete: Combined Hyperlipidemia

Drugs & Therapeutics for Obsolete: Combined Hyperlipidemia

Drugs for Obsolete: Combined Hyperlipidemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fenofibrate Approved Phase 4 49562-28-9 3339
2
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
3 Colesevelam Hydrochloride Phase 4
4 Rosuvastatin Calcium Phase 4 147098-20-2
5 Calcium, Dietary Phase 4
6
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
7
Pravastatin Approved Phase 3 81093-37-0 54687
8
Atorvastatin Approved Phase 3 134523-00-5 60823
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
10
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
11
Torcetrapib Investigational Phase 3 262352-17-0 159325
12 Micronutrients Phase 3
13 Trace Elements Phase 3
14 Vitamins Phase 3
15 Vitamin B9 Phase 3
16 Folate Phase 3
17 Vitamin B Complex Phase 3
18 Nutrients Phase 3
19 Vitamin B3 Phase 3
20 Nicotinic Acids Phase 3
21 Vasodilator Agents Phase 3
22
Anacetrapib Investigational Phase 2 875446-37-0
23 Fenofibric acid Approved 42017-89-0
24
Mannitol Approved, Investigational Early Phase 1 69-65-8 453 6251
25
chenodeoxycholic acid Approved Early Phase 1 474-25-9 10133
26 Gastrointestinal Agents Early Phase 1
27 Cathartics Early Phase 1
28 Laxatives Early Phase 1

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
2 The Effects of the Combination of Welchol and Tricor Compared to TriCor Alone in Patients With Mixed Hyperlipidemia Completed NCT00754039 Phase 4 colesevelam HCl tablets and fenofibrate tablets;fenofibrate tablets and Welchol placebo tablets;fenofibrate tablets and Welchol placebo tablets
3 A Double-blind, Double Dummy, Phase IV, Randomized, Multicenter, Parallel Group, Placebo Controlled Trial to Evaluate the Effect of Rosuvastatin on Triglycerides Levels in Mexican Hypertriglyceridemic Patients Completed NCT00473655 Phase 4 rosuvastatin
4 The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal Completed NCT00552747 Phase 4 fenofibrate;placebo
5 An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia Withdrawn NCT02069106 Phase 4
6 Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Patients With Mixed Hyperlipidemia and Two or More Risk Factors to Cardiovascular Disease. Withdrawn NCT00738985 Phase 4 ezetimibe/simvastatin 10/20 mg + placebo;ezetimibe/simvastatin 10/20 mg + MK0524A
7 Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient: Multi Center, Randomized, Double-blind, Parallel-group, Therapeutic Confirmatory Study. Unknown status NCT01956201 Phase 3 Atorvastatin 20mg;Fenofibrate 160mg
8 A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia Completed NCT00093899 Phase 3 ezetimibe (+) simvastatin
9 Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia Completed NCT00092573 Phase 3 MK0653, ezetimibe;Comparator: fenofibrate monotherapy
10 Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia Completed NCT00092560 Phase 3 MK0653, ezetimibe;Comparator: fenofibrate monotherapy
11 A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia Completed NCT00269217 Phase 3 niacin (+) laropiprant (+) simvastatin;Comparator: niacin (+) laropiprant;Comparator: simvastatin
12 A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia Completed NCT00269204 Phase 3 niacin (+) laropiprant;ER-niacin
13 A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia Completed NCT00289900 Phase 3 MK-0524A;Atorvastatin;Simvastatin
14 A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With Atorvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 10 mg Atorvastatin Alone Completed NCT00362934 Phase 3 fenofibrate / simvastatin;Atorvastatin
15 A Multicenter, Double-Blind, Randomized Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Simvastatin Alone. Completed NCT00352183 Phase 3 Fenofibrate/Simvastatin;Simvastatin
16 A Multicenter, Double-Blind, Randomized, Active Comparator, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 20 mg Simvastatin Alone Completed NCT00349375 Phase 3 Fenofibrate/Simvastatin;Fenofibrate/Simvastatin;Simvastatin
17 A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin Completed NCT00376584 Phase 3 MK-0524A;ER Niacin;Placebo
18 Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia Completed NCT00139061 Phase 3 Torcetrapib/Atorvastatin;Fenofibrate
19 A Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK0524A Versus Niacin Extended-Release Completed NCT00378833 Phase 3 niacin (+) laropiprant;niacin
20 A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Pravastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Pravastatin Alone Completed NCT00362206 Phase 3 Fenofibrate/Simvastatin;Fenofibrate/Simvastatin;Pravastatin
21 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Lipid-Altering Efficacy and Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia Completed NCT00536510 Phase 3 laropiprant/niacin (MK0524A);Comparator: placebo
22 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of TRIA-662 Completed NCT00758303 Phase 2, Phase 3 Low Dose TRIA-662;High Dose TRIA-662;Placebo for TRIA-662
23 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA) Completed NCT00519714 Phase 2, Phase 3
24 Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia Terminated NCT00134238 Phase 3 torcetrapib/atorvastatin;atorvastatin
25 A Phase 2 Randomized, Double-Blind, Dose-Response Efficacy and Safety Study of SCH 900271 Compared to Placebo in Subjects With Primary Hypercholesterolemia (Familial and Nonfamilial) or Mixed Hyperlipidemia Completed NCT00941603 Phase 2 SCH 900271 15mg;SCH 900271;SCH 900271;SCH 900271;SCH 900271;Placebo
26 A Randomized, Double-blind, Placebo-controlled, Forced Dose-escalation, Multi-center Pilot Study to Evaluate the Lipid Regulating Effects of TRIA-662 (1-methylnicotinamide Chloride) Completed NCT02008084 Phase 2 TRIA-662;Placebo
27 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of MK-0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia Terminated NCT00325455 Phase 2 MK0859
28 A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED) Completed NCT00565292 Phase 1 MK0859
29 Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy. Unknown status NCT01974297 Atorvastatin 10mg, fenofibric acid 135mg;atorvastatin 20mg
30 Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia Completed NCT00465751 Early Phase 1 chenodeoxycholic acid;placebo capsules
31 Genetic Epidemiology of Hypertriglyceridemia Completed NCT00005368
32 A Multicenter, Open-label, 30-week Observational Clinical Study to Examine the Progress of Patients After Leaving the Cardiology Clinic or Unit Due to Acute Cardiovascular Event. Completed NCT01770210 Patients on atorvastatin treatment
33 Prevalence and Mutation Rate of Lipa Gene in LIPIGEN Subjects With Clinical Diagnosis of FH Recruiting NCT03984149

Search NIH Clinical Center for Obsolete: Combined Hyperlipidemia

Genetic Tests for Obsolete: Combined Hyperlipidemia

Anatomical Context for Obsolete: Combined Hyperlipidemia

MalaCards organs/tissues related to Obsolete: Combined Hyperlipidemia:

41
Heart, Endothelial, Testes, Kidney, Liver, Thyroid, T Cells

Publications for Obsolete: Combined Hyperlipidemia

Articles related to Obsolete: Combined Hyperlipidemia:

(show top 50) (show all 211)
# Title Authors PMID Year
1
Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP). 38
31311144 2019
2
Prevalence of dyslipidemia among students of a Yemeni University. 38
31435407 2019
3
Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia. 38
30538126 2019
4
Fenofibrate Solid Dispersion Processed by Hot-melt Extrusion: Elevated Bioavailability and Its Cell Transport Mechanism. 38
30674259 2019
5
The clinical importance of recognizing capecitabine-induced hypertriglyceridemia: A case report and review of the literature. 38
30126762 2018
6
The spectrum of type III hyperlipoproteinemia. 38
30318453 2018
7
Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects. 38
29157655 2018
8
FAMILIAL COMBINED HYPERLIPIDEMIA: CURRENT KNOWLEDGE, PERSPECTIVES, AND CONTROVERSIES. 38
30307446 2018
9
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population. 38
29321358 2017
10
Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. 38
28098593 2017
11
Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy. 38
28391878 2017
12
L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study. 38
27914033 2017
13
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. 38
27497929 2016
14
[Prevalence of Hypertriglyceridemia: New Data Across the Russian Population. The PROMETHEUS Study]. 38
28290909 2016
15
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. 38
27240673 2016
16
[Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma]. 38
26688184 2016
17
Biochemistry of Statins. 38
26975972 2016
18
[Prevalence of dyslipemia in Aristide le Dantec biochemistry laboratory in Dakar Senegal]. 38
28292030 2016
19
Plasma sICAM levels during standard exercise test are higher in postmenopausal women with mixed hyperlipemia. sICAM level in postmenopausal women. 38
29676885 2016
20
Prevalence and Risk Factors Associated with Dyslipidemia in Chongqing, China. 38
26516874 2015
21
Prevalence of and Risk Factors for Type 2 Diabetes Mellitus in Hyperlipidemia in China. 38
26297334 2015
22
Efficacy of statin monotherapy or in combination with coenzyme a capsule in patients with metabolic syndrome and mixed dyslipidemia. 38
25883708 2015
23
Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital. 38
26604773 2015
24
Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. 38
26206619 2015
25
Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? 38
26134926 2015
26
Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study. 38
26285608 2015
27
Does airway surgery lower serum lipid levels in obstructive sleep apnea patients? A retrospective case review. 38
25503376 2014
28
[The fixed combination of pravastatin and fenofibrate: what can it provide?]. 38
25043541 2014
29
[Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia]. 38
25043545 2014
30
Adrenal and Thyroid Supplementation Outperforms Nutritional Supplementation and Medications for Autoimmune Thyroiditis. 38
26770099 2014
31
Dyslipidemia, obesity and other cardiovascular risk factors in the adult population in Senegal. 38
25815102 2014
32
Lipid profile frequency and the prevalence of dyslipidaemia from biochemical tests at Saint Louis University Hospital in Senegal. 38
25018825 2014
33
Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control. 38
25371655 2014
34
Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study. 38
24382338 2014
35
Is combined lipid-regulating therapy safe and feasible for the very old patients with mixed dyslipidemia? 38
24454328 2013
36
The association between hyperuricemia and betel nut chewing in Taiwanese men: a cross-sectional study. 38
24308550 2013
37
Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. 38
24239156 2013
38
The effects of the decaffeination of coffee samples on platelet aggregation in hyperlipidemic rats. 38
23780748 2013
39
The need for combination drug therapies in patients with complex dyslipidemia. 38
23812840 2013
40
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. 38
22305632 2013
41
Hypertriglyceridemia. 38
23525082 2013
42
Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. 38
22943927 2012
43
Effects of baked products enriched with n-3 fatty acids, folates, β-glucans, and tocopherol in patients with mild mixed hyperlipidemia. 38
23529988 2012
44
[Clinical research of Chinese medicine syndromes of hyperlipidemia inpatients]. 38
23163138 2012
45
Efficacy and safety of statin and fibrate combination therapy in lipid management. 38
23158983 2012
46
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups. 38
22500948 2012
47
Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. 38
22481068 2012
48
Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia. 38
22651832 2012
49
The work-up for mixed hyperlipidemia: a case study. 38
22393551 2012
50
Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. 38
22269152 2012

Variations for Obsolete: Combined Hyperlipidemia

Expression for Obsolete: Combined Hyperlipidemia

Search GEO for disease gene expression data for Obsolete: Combined Hyperlipidemia.

Pathways for Obsolete: Combined Hyperlipidemia

GO Terms for Obsolete: Combined Hyperlipidemia

Sources for Obsolete: Combined Hyperlipidemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....